BillionToOne, Inc. (BLLN) Earnings Call Transcript
May 6, 2026
Earnings Call Speaker Segments
Thanks for joining us this afternoon, everyone, on today's conference call. Joining me from BillionToOne, Inc. are our cofounder and chief executive officer, Oguzhan Atay, along with our chief financial officer, Ross Taylor. BillionToOne, Inc. released its financial results today for the first quarter, which closed on 03/31/2026. That press release is available on the company's website. Before we begin, please note that statements made during this call may be forward-looking under federal securities laws. Such statements, which concern future events, might address our financial outlook and performance, market size, our products and services, reimbursement coverage, future clinical performance, and comparable matters. Before we go further, a note of caution: what we're sharing represents our best assessment as of right now, and the outcomes we ultimately see could end up meaningfully different from anything suggested or stated in forward-looking remarks. You can find the risk factors that might lead to such differences described in the documents we file with the SEC — that includes the Annual Report on Form 10-K we filed earlier, the Quarterly Report on Form 10-Q that we'll submit once this call concludes, and the Current Report on Form 8-K that went in today. Everything forward-looking we say on this call speaks only as of today's date, 05/06/2026. Should anyone replay or revisit this call after today, the material covered here might no longer be up to date or correct. That's BillionToOne, Inc. The company states it has no duty to revise any forward-looking statements publicly—whether due to fresh information, upcoming occurrences, or anything else—unless the law demands it. Having said that, I'll now hand things over to Oguzhan.
I want to thank everyone for being on this call for our Q1 2026 earnings. To begin, I'd like to express appreciation to the people who work here — they put in enormous effort and care to create and provide outstanding tests for our patients, which enhance their treatment and take away the anxiety of not knowing. Before we get into the quarter's numbers, let me restate the four pillars that I think set us apart as a different kind of molecular diagnostics business. The first is our groundbreaking technology platform, powered by our patented QCT — Quantitative Counting Template — which delivers single-molecule sensitivity and precision alongside next-generation sequencing. Using that platform, we've created distinctive, category-defining offerings in prenatal as well as oncology. Thanks to these differentiated products, we've expanded exponentially over the past six years, and even now that we've reached scale, we're compounding at a rate we consider uncommon for this industry. Even so, plenty of runway remains, since the prenatal and oncology cfDNA market opportunity could surpass $100 billion in the U.S. over time. Beyond growing quickly, we've also delivered a strong gross margin profile, now exceeding 70%, and there's still considerable room to expand it further via ASP growth and lower COGS per test. Finally, because we've cultivated fiscal discipline and efficient operations that incorporate AI and automation, we reached GAAP profitability and positive cash flow while carrying under 10% of the accumulated deficit our public competitors have. To sum up, we're still moving toward our long-term objective, which hasn't changed: creating a category-defining generational company and earning a place in the S&P 500. Our performance in the first quarter was exceptionally strong across all four pillars. We posted a rule of 100-plus for the third quarter running, and this time we combined it with profitability at a level rarely seen in a high-growth company — another quarter of strong growth, wider margins, positive operating income, and positive cash flow. Going through the results pillar by pillar: in prenatal, we expanded fetal antigen NIPT and launched FNAIT NIPT, and in oncology we launched PGx and CH in February; then, after the quarter closed, we introduced a category-redefining prenatal test called Unity Confirm. Unity Confirm is the first noninvasive fetal cell-based confirmation assay aimed at high-risk NIPTs; on the oncology side, our product roadmap is still on schedule. For our Response coverage submission, we answered every MolDX comment, and our tumor-naive MRD launch remains on track for release before this year ends. As new products keep coming, the business keeps expanding, with test volume up 44% year over year and total revenue up 84% year over year, both consistent. On the third pillar, we've kept making headway with in-network contracts. Most significantly, we signed an agreement with Anthem, which brings our total contracted lives in the United States to 300 million. Since our average selling prices rose 28% from the prior year to $571 for each test, and since we kept our cost of goods sold at $153 per test, even with a larger share of oncology tests carrying a higher COGS, our gross margins grew to 73% during Q1 — a solid gain of nine percentage points compared with a year earlier. Then, regarding our fourth pillar, because gross margins grew and because we ran the business more efficiently, we turned in an outstanding profitability picture during the first quarter, posting a 16% GAAP operating margin along with a 24% adjusted EBITDA margin, which lifted our cash balance to $537.5 million when the quarter closed. Let me go through each pillar individually. Starting with our first pillar: on May 1, only five days back, at the ACOG Annual Meeting, we advanced the field yet again by introducing something we expect will come to be regarded as the decade's key innovation in prenatal genetics. Unity Confirm is the very first and sole noninvasive confirmation assay built for high-risk pregnancies. It embodies what numerous people in our field have considered for a long time to be the holy grail of noninvasive prenatal testing. Unity Confirm captures and sequences intact circulating fetal cells drawn from a maternal blood sample, which yields 100% fetal fraction. For context, standard cell-free DNA tests depend on tiny fractions of fetal DNA within maternal plasma. Through isolating and sequencing complete fetal cells directly, Unity Confirm occupies a fundamentally separate category. We introduced Unity Confirm as a specialized offering, meant as a follow-up for high-risk pregnancies flagged by our Unity Aneuploidy screen. At present, when an NIPT comes back high risk, the following step is invasive diagnostic testing, which is becoming less and less accessible in maternity care deserts and additionally involves a small miscarriage risk. Most patients either cannot or decide not to go ahead with invasive diagnostic confirmation. Unity Confirm fills this vital clinical gap. It provides these patients and their physicians with a noninvasive choice. Our early results have demonstrated 100% concordance against invasive diagnostics, and we are presently enrolling patients in what we think is the biggest prospective circulating fetal cell-based study ever run with concordance to invasive diagnostics. We also created a thorough launch campaign surrounding Unity Confirm. Over 500 providers either attended the launch or viewed it on the live stream. We expect Unity Confirm will further boost the differentiation among our Unity product offerings. Now for our second pillar, scalable rapid growth: our leadership in product innovation together with our expanding commercial team kept generating strong test volume during the quarter. During Q1, we delivered roughly 188 thousand tests, which equals 44% growth versus a year ago, plus strong sequential growth in both product lines, with prenatal volumes up approximately 10% from the previous quarter and oncology volumes up approximately 25% from the previous quarter. Notably, on the oncology side, roughly 60% of NorthStar Select orders now choose to opt in to CH, which shows growing physician awareness of how important it is to distinguish tumor-derived from non-tumor-derived variants in liquid biopsy. In Q1, our overall revenue increased at an even quicker pace, posting 84% growth compared with the same period a year earlier. That came from a 44% rise in test volume versus last year, along with a 28% increase in ASP year over year. When we break it down by segment, prenatal and oncology both added significantly to that growth. Prenatal revenue for the first quarter came to $97.7 million, a 72% jump from a year ago, fueled by robust volume gains, solid commercial execution, and extra momentum from our fetal antigen test products that launched at SMFM in February. This further demonstrates how differentiated Unity is and how durable our prenatal growth has been. Oncology revenue reached $10.7 million in the first quarter, nearly five times what it was last year, with an annualized revenue run rate of $43 million. The oncology ramp reflects growing adoption of NorthStar Select and NorthStar Response, the recent PGx and CH launches, and strong execution from our oncology commercial team; we still see considerable opportunity ahead in oncology as we keep expanding our sales team, generating clinical evidence, and working toward Medicare coverage for NorthStar Response. Before we get into ASPs and COGS, I'd like to point out a significant milestone this quarter. I'm happy to share that BillionToOne, Inc. is now in network with Anthem, one of the biggest health insurers in the United States.
So this takes our total contracted lives up to roughly 300 million across the U.S., which works out to over 90% of patients. After that in-network deal we told you about last quarter with UnitedHealthcare, bringing Anthem on board makes our market access position even stronger. Like I've said before, when you have an in-network contract, it takes away friction for physicians and patients alike, it widens access, and eventually it leads to ASPs that are higher and more predictable. Now on ASPs, growth continued in the first quarter, with overall ASP rising to $571 per test, which is a 28% increase year over year and a $10 per-test bump sequentially; and that happened even with the mostly temporary impact of coinsurance and deductibles being reset at the start of the year. We still see plenty of room for ASP expansion going forward, and that's driven by more Medicaid adoptions of the carrier panel PLA code for our test, the ongoing mix shift toward oncology tests that carry higher ASPs, and eventually Medicare coverage for our NorthStar Response test. Beyond pushing ASP growth, we've stayed dedicated to our operating model of continuous improvement when it comes to bringing down COGS per test. Our overall COGS per test came in at $153 for the first quarter, which is down 5% sequentially and up just 1% year over year. That was a really notable accomplishment when you consider two things: first, the ongoing mix shift toward a bigger share of oncology tests, which carry higher COGS per test; and second, the COGS effect from recent product launches and enhancements, like CH. While we do expect to keep seeing COGS per test come down, particularly in oncology, over the long run we expect overall COGS per test to rise gradually as our oncology business keeps growing faster. With our overall ASPs still climbing and our overall COGS per test holding roughly steady, our gross margin profile widened again in the first quarter. Gross margins came in at 73% for Q1, which is a nine percentage point increase year over year from 64% in 2025 and a two percentage point increase sequentially from 71% in Q4 2025. That gain was mainly the result of continued growth in prenatal ASP and major COGS reductions in oncology. We're pleased with the margin trajectory in both segments. While faster growth in our oncology business can move margins around — since oncology currently runs lower margins because of lower volume scale and because Medicare coverage of Response hasn't happened yet — we expect to keep overall gross margins strong, above 70%. And lastly, our first quarter performance let us keep making important progress toward our long-term goals. We posted a 16% GAAP operating margin and a 24% adjusted EBITDA margin in Q1 while still investing significantly in our sales force, in new product launches, and in generating clinical evidence. Let me point out once more that we reached this level of profitability at a far smaller size than the rivals we compete against, all while expanding more quickly and carrying under 10% of the cumulative losses they have built up. That mix of expansion and profit demonstrates how distinctive our technology is, how differentiated our product lineup is, and how disciplined we are in operations. Having said that, I'll hand things over to Ross so he can walk through our financial results and the revised guidance for 2026, after which I'll wrap up.
Thanks, Oguzhan. Just like Oguzhan mentioned, we delivered strong results in Q1 of 2026, combining revenue growth of 84% year over year with a 16% operating margin and a 24% adjusted EBITDA margin. Q1 2026 revenue came to $108.4 million, compared with $59.0 million in Q1 2025, which works out to an 84% increase. We saw solid momentum across both prenatal and oncology offerings this quarter. Prenatal revenue — made up of clinical testing along with clinical trial support and other services — grew 72%, hitting $97.7 million in Q1. Oncology revenue jumped nearly 400%, landing at $10.7 million in Q1 2026 versus the same quarter a year ago. The primary driver of our overall revenue increase was greater test volume across both prenatal and oncology, combined with ongoing rises in our average selling prices for those two areas. In the first quarter of 2026, true-up revenue totaled $9.2 million, compared with $8.4 million during Q4 2025 and $2.9 million in Q1 2025. If you set true-up revenue aside, our total revenue for Q1 climbed 77% relative to the prior-year quarter. We recorded $79.1 million in gross profit for Q1 2026, up from $38.0 million in Q1 2025, which works out to a 73% gross margin in Q1 2026 versus 64% in Q1 2025. The improvement in gross margin was driven chiefly by a higher overall ASP. In Q1 2026, total operating expenses came to $61.2 million, compared with $40.3 million for the same quarter a year earlier, which works out to a 52% rise. Within that total, R&D expense stood at $14.7 million in Q1 2026, against $10.4 million in the prior-year comparable quarter. SG&A expense amounted to $46.6 million in Q1 2026, compared with $29.9 million in the same quarter last year. We continue putting money into our commercial team, R&D, and clinical evidence generation, and even so, operating expenses measured as a share of revenue dropped significantly. Operating income in Q1 2026 was $17.8 million, compared with an operating loss of $2.3 million in Q1 2025. Our operating profit margin for Q1 hit 16%, a sizable improvement over the 11% operating margin delivered in Q4 2025. For the quarter, adjusted EBITDA came in at a 24% margin. In Q1 2026, net income available to common shareholders reached $18.0 million, equal to $0.34 per diluted share, compared with a net loss of $4.0 million, or $0.39 per diluted share, during the same period of 2025. Operating cash flow less capital expenditures totaled $11.0 million in Q1 2026. Our capital position is strong, and our balance sheet is very healthy; we closed the first quarter with $537.0 million in cash and equivalents; in our view, that balance sheet sets us up for robust growth ahead, especially since we intend to keep running the business for profitability and positive cash flow. Lastly, I will share an update regarding our full-year guidance for 2026. For 2026, our total revenue guidance is moving up to somewhere between $450 million and $465 million. That works out to growth of 48% to 52% versus the full year of 2025. Both ends of that range sit $20 million higher than the numbers we shared back in early March, which were $425 million to $445 million. Two things drove this increase: the strength of our business in Q1, and our confidence that new payer contracts will lift our ASPs for the remainder of the year. Beyond that, our plan is to operate in a way that sustains profitability close to current levels, all while continuing to make significant investments. At this point I'll hand the call back over to Oguzhan for closing remarks.
Thanks, Ross. To sum up, we're changing health care a single molecule and a single patient at a time. As I look forward, what gives me confidence is how durable and scalable the base we've established is. This isn't a tale that hinges on a single catalyst. It's a tale of several mutually strengthening drivers operating in tandem over time. Every product we bring to market makes our platform stronger. Every study we release adds further proof of the clinical utility of our technology. Every payer contract, among them our landmark deals with UnitedHealthcare and now Anthem, bolsters access and underscores the worth of what we offer. During Q1, we introduced Unity Confirm, an offering unlike any other, which sets our prenatal product portfolio even further apart. And we took meaningful steps toward keeping our oncology product roadmap on schedule. Our robust revenue growth carried on — 84% year over year — producing a $434 million annualized revenue run rate. Alongside that revenue growth, we've delivered striking gross margins of 73%, a rise of nine percentage points versus a year ago, even with subscale COGS and ASPs, particularly in oncology. Finally, we've demonstrated that fast growth need not sacrifice profitability, posting a striking 16% GAAP operating margin and 24% adjusted EBITDA margin. A team of deeply motivated, mission-driven people powers us, showing up daily with a common purpose to make a meaningful difference in patients' lives. That commitment shows in how strong our results are and keeps driving our momentum. As we look forward, our ambition is unchanged: to build a category-defining company, earn a place in the S&P 500, transform molecular diagnostics, and help reshape health care. We're happy with how we've begun the year and look forward to updating you as it goes on; we'll now open the call for questions. Over to the operator.
Ross, to kick things off regarding the revenue guidance increase — does that include a larger volume piece, or is it mostly driven by ASPs? And could you also speak briefly about how volume will trend across the remaining portion of this year?
Absolutely, Dan. As I mentioned somewhat in my prepared remarks, that upward revision to guidance stemmed from the momentum achieved during Q1, incorporating that into our outlook, plus an anticipated ASP bump from a number of added payer contracts we signed after 2026 began. So we aren't really building in any volume growth relative to what we previously expected, beyond the solid outcomes from Q1 — it's chiefly a result of ASP improvement and, again, the robust Q1 performance. Regarding how volumes will flow through the year, the main point I'd offer is that Q4 tends to run slower for us because of holiday seasonality and various other considerations. Beyond that, I'd look for modest quarter-over-quarter gains in Q2 and Q3, though Q4 is seasonally our softest quarter.
All right, and then regarding gross margins, that increase was quite significant. Our out-year forecast doesn't include any mid-70s figure at all. So as new products are added to the portfolio, how sustainable is that? At a minimum, the 68% — 69% assumption for this year appears low unless something is going to step down in the back half. So could you perhaps assist us with that?
Certainly. As we mentioned during our remarks, we anticipate 70% or better gross margin throughout the year. There might be some quarterly volatility in that, but 70% or better gross margin, I would expect, is something we can maintain for this calendar year.
Let me give you a bit of color on that. When it comes to these agreements — Anthem and UnitedHealthcare in particular, plus others too — we're now putting pen to paper on about 5 to 10 of them nearly every single month, and each one is steadily lifting our ASPs. Prenatal, in my view, stands out as one of the most impressive molecular diagnostics businesses around when you look at gross margin. As everyone knows, absent Response Medicare coverage, oncology carries thinner margins, and that segment is expanding at a tremendous clip — 25% quarter over quarter. So near term, you've got this tension where oncology grows faster while prenatal delivers the gross margins. That will hold back additional expansion for now, though we still anticipate it coming in above 70%. Down the road, once both of these product lines reach maturity, we believe both portfolios should comfortably sit above 75%.
Nice work on the solid quarter. I'd like to ask you about Unity Confirm; it sounds like a fairly compelling and novel offering. Oguzhan, how would you gauge the size of that market? So, taking the roughly 3.6 million births in the U.S. as a starting point, what portion of those do you figure would qualify for Confirm? And my understanding is that this launches later this month. Do you anticipate gaining broader reimbursement coverage for it as an add-on? And on that note, could you discuss the clinical trial currently enrolling? What's your estimate for how long it will take to get patients enrolled in that study?
Mark, thanks for asking. When it comes to reimbursement or added revenue from Unity Confirm, our expectation is that it will be quite minimal, if anything at all. That's because only around 0.5% of patients — perhaps as much as 1% — would test positive on a cell-free DNA test and therefore qualify for it. What matters most about Unity Confirm, I think, is that a patient can only receive this test if they've used Unity Aneuploidy. Our belief is that this will make our Aneuploidy offering strongly differentiated, and interest will grow in choosing our Unity Aneuploidy platform rather than any other, so that when a positive high-risk result occurs, only then does the patient become eligible for testing with Unity Confirm. With this exclusive offering — noninvasive confirmation for these high-risk pregnancies — we see it as yet another driver of volume, not from the Unity Confirm volume by itself, but since patients qualify for it only if our Aneuploidy screening served as their frontline screen in the first place. As for the clinical trial's timing: it's a very large trial, and invasive testing across the United States has dropped considerably over time. Fewer patients than in the past are undergoing invasive confirmation, which shows just how essential this offering is and the clinical utility it delivers. That said, it also means the timeline for a very large clinical trial such as this one could readily run anywhere from one to three years.
I just want to make sure — will both amnio and CVS be used as comparators for these patients?
In the way the clinical trial has been set up, CVS and amniocentesis are both included, yet the primary endpoint, the main utility, is versus CVS, since it aligns with the cell type we are assessing and also with the CVS timeframe we are assessing.
Great, and that's my final question. It's good to see Anthem get up and running. My understanding is that United launched on April 1 — can you verify that? And when does Anthem go live?
United's effective date was April 1. Anthem has already gone into effect.
Andrew, thanks for that. On Unity Confirm — could you give us a broad view of the cell capture technology? What role does it play across the whole prenatal genetics platform, and what future uses does it open up when you look several years ahead?
This has been the holy grail of prenatal testing, something people have pursued for 20 years now. Getting these cells is incredibly hard. If you consider cell-free DNA testing, roughly 5% to 10% of that DNA comes from the fetus. And with these trophoblasts — these fetal cells — you are dealing with what is genuinely a one-in-a-billion kind of cell. The process demands more labor and is more challenging, which is why it is aimed at confirming high-risk cases instead of serving as frontline testing; yet as you might expect, a major constraint of cell-free DNA testing, particularly when you move toward rarer conditions, involved worries about PPVs. A noninvasive confirmation assay effectively eliminates that worry. Over the long run, I don't view cell-based methodology as something that replaces cell-free DNA methodology — because of both cost and how labor-intensive Unity Confirm or any other cell-based approach is — yet it genuinely addresses the core issue with cell-free DNA testing, namely the widening gap between screening and diagnostics. That can genuinely allow cell-free DNA testing to become more comprehensive and more widely adopted too.
Next, I'd like to ask about how you're prioritizing capital allocation. You mentioned keeping profitability intact even while putting substantial money into investments, if I understood correctly. So my assumption is that cash ought to keep increasing going forward. What's the right way for us to think about how you'll deploy that cash and approach capital allocation from this point?
At this moment in time, we haven't made any particular plans regarding what to do with that cash. Our intention is to stay profitable while continuing to put money into a range of different areas.
You said the MRD launch remains on schedule. What tangible catalyst comes next that we ought to watch for? And should that be data, do you already know which forum you'd present it through — a publication or a conference?
When we launch MRD, data will accompany that launch. It won't arrive before launch; it will arrive alongside launch. Whether a particular conference will host it, I can't say; it could basically be a manuscript that we put out.
Thanks for that; and please remind everyone, what's the ratio of Response to Select in this quarter? And on a separate note, ACOG guidelines got updated last week. Given that, how far has prenatal reimbursement contracting moved along so far this year, particularly regarding expanded carrier screening and 22q? Based on that, what do you anticipate as we exit 2026, and in what ways could this influence your outlook on next year's ASPs?
Around coverage policies, we haven't observed any particular shifts. During Q1 we managed to become in network with an increasing number of payers, and right now that stands as the main driver behind our ASP growth. When it comes to Response versus Select, the ratio looks comparable; roughly two Response for every one Select. Every physician has a different way of using them. Certain physicians repeat both Select and Response, making it a one-to-one ratio. Others start with one Select and one Response, then follow up with two or three or four Response tests until progression appears, and at that stage they turn to a Select test. The blended average remains at two Response to one Select, which truly reflects what Medicare coverage of a Response test is worth to us. That's the reason we've been pushing hard on that front.
Hello. Sebastian Sandler here, filling in for Casey. I appreciate you fielding this. To start, I'd like to ask about how quickly sales representatives are getting up to speed. Could you tell us how many reps were fully ramped when Q1 ended? After that, what's your current outlook for the number of fully productive reps by the time this year wraps up? If it's possible to break that out between prenatal and oncology, that would be extremely useful. Beyond that, any additional detail on how the ramp-up process is going would help — is it requiring more time or less time than you originally anticipated?
Thanks, Casey. Regarding the figures we provided during the March earnings call — we're roughly where we expected to be. We won't report each quarter the precise count of reps who've completed ramping, though their output continues to align with what we anticipated last quarter.
Turning to oncology ASPs, it seemed they came down slightly on a sequential basis. My guess is that this was related to NorthStar Select, perhaps because true-ups fell away. So could you shed some more light on that? And then regarding how ASPs will move through the remainder of the year — is stability the likely path, or should we think of it as weighted toward the back half once some of these newly signed contracts begin to contribute?
My understanding is that oncology ASPs, mostly when true-up is excluded, came in quite close to before. The true-up figures shift quarter to quarter, and that can affect precisely what gets recognized. That said, nothing meaningful has changed regarding the way our oncology tests get paid. Broad coverage and reimbursement apply to NorthStar Select, while NorthStar Response lacks them. Once Medicare coverage is in place for NorthStar Response — something we expect near the close of the year — we anticipate the NorthStar Response ASP will be considerably higher.
Hello. Skye here, filling in for Dave. Appreciate you taking the question. Perhaps regarding the health system pipeline, what's the status as of now? Do health system-related adoptions still remain outside the guide?
Health system adoption is something we do work on, though how long health system adoptions take can vary quite a bit. As a result, aside from sales team territory growth expectations, which are included as a standard part of our projections, it isn't directly embedded in the guide.
Understood. All right, thank you. Then moving on, could you give us a bit more detail regarding your view of cancer monitoring across the coming years, along with when that might happen?
Could you say that again?
Yes. In the coming years, how do you expect adoption of cancer monitoring to unfold, and what's the timing around it?
When you mention cancer monitoring, are you talking about adoption tied to NorthStar Response, or do you mean more surveillance in relation to MRD?
Having more monitoring around MRD would be excellent.
At present, no MRD test is offered by us, though we are engaged in developing a tumor-naive version of such a test. It is our view that right now, academic centers account for the bulk of MRD usage, with colorectal cancer being the main application. Tissue is far more accessible in that particular area than it is in other kinds of cancer. Our expectation is that a tumor-naive assay matching, or even exceeding, the sensitivity of the many tumor-informed assays would gain acceptance far more readily among community oncologists, who are responsible for the care of more than 80% of oncology patients across the United States. Therefore, despite the fact that colorectal cancer and academic centers represent where most uptake happens at this time, ultimately community oncologists relying on tumor-naive tests will drive the larger expansion of MRD, which explains why so much of our effort goes toward the tumor-naive dimension of our test, despite a tumor-informed test being far simpler to create; indeed, we have constructed an ultra-sensitive tumor-informed test in-house purely to use as a comparison standard for our tumor-naive test.
Hi there, and thanks. Good afternoon. Ross, I've just got a couple of things to ask. First, aside from those Q1 true-ups, I'd like confirmation on how much in the way of extra true-ups you've built into the fresh guidance for the remaining portion of the year. Second, can you address why accounts receivable jumped so much during the first quarter?
Of course. On the true-up side, the only true-up revenue reflected in our guidance is the historical Q1 figures we've already reported; as for the later quarters, no, nothing of that kind is baked into the guide. Turning to the AR movement: during Q1 we signed a number of contracts, and some of them landed late in the quarter as well. Reimbursement on those won't reach us for a few months yet, and that new contracting activity accounted for roughly 50% of the quarter's AR increase — or nearly 50% of it. My expectation is that it will decline, whether that happens by Q2 or, for sure, by Q3. It simply hinges on how quickly these efforts move forward.
Hi, I'd really like to explore the Q1 volumes a little more. Last quarter, you mentioned a rise in active ordering providers. Could you perhaps address what portion of this quarter's volume came from providers who are new, as opposed to repeat orders from those integrated before?
Tycho, thanks for asking. The count of newly active ordering providers we brought on this quarter looks very much like what we added in earlier quarters; no difference has appeared. Honestly, the main reason test volume shifts from one quarter to another is how many accessioning days fall within the quarter and the timing of when those providers become active across it. For us, Q4 is typically seasonally slow; whatever gap exists between Q4 and Q1 stems from the count of accessioning days plus the holidays during the quarter, which pushes test volume down artificially.
Then, regarding Unity Confirm, I'm curious about your perspective on market share trends right now. There have also been rival product introductions. How do you see share dynamics at present?
We aren't observing a major effect on how we bring in new providers and new accounts. Unity Confirm admittedly generates a bit of chatter, but the reality that we brought on a comparable count of newly active ordering providers during Q1 and Q4 — comparable to earlier quarters — genuinely demonstrates that providers find our products compelling and that we're performing effectively. Unity Confirm serves as an additional catalyst, one more incentive for providers to adopt our test. Unlike certain earlier product introductions of ours, this specific offering can only be obtained when a provider has requested Unity Aneuploidy as a frontline screen, and we think that will establish our test far more as a frontline option in specific situations where previously they might have turned to our test as a second line. Occasionally, with our fetal antigen testing, we'd get an additional aneuploidy order despite the frontline test being a rival's product, or we'd get tests where our aneuploidy gets ordered because other tests produced no-calls or yielded incorrect results; here, we only make Unity Confirm available when our test has served as a frontline test, meaning it will be a significant catalyst for test volume.
Then for my final question, I'd like to get a sense of the schedule with MolDX regarding NorthStar Response. There's a lot of talk out there about possible holdups at MolDX and extended wait times for new submissions. How likely is it that this slips to next year?
MolDX hasn't presented us with any problems at all. Their replies are coming back inside the 60-day window they've committed to, and our exchanges with MolDX were highly productive. A delay isn't something we foresee. In fact, it could land somewhat sooner than our initial expectation.
Appreciate it, operator. And thanks to everyone for being on today's call. We're looking forward to talking with all of you on our next call in a few months. Have a good day.
Thanks very much, everyone, for joining us on this call. That brings the program to an end. You're welcome to hang up at this point. Have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete BillionToOne, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to BillionToOne, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.